EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Conclusions The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2016 EAU-ESTRO-SIOG Guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are the first endorsed by the European Society for Therapeutic Radiology and Oncology and the International Society of Geriatric Oncology and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). Patient summary In men with a rise in their PSA levels after prior local treatment for prostate cancer only, it is important to balance overtreatment against further progression of the disease since survival and quality of life may never be affected in many of these patients. For patients diagnosed with metastatic castrate-resistant prostate cancer, several new drugs have become available which may provide a clear survival benefit but the optimal choice will have to be made on an individual basis. This paper summarises the 2016 European Association of Urology (EAU)- European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Prostate Cancer Guidelines Prostate Cancer Guidelines. Standard therapy for PSA relapse after radical prostatectomy is salvage radiotherapy at a PSA of <0.5ng/ml. Recommendations for treatment of progression after primary radiotherapy include salvage radical pro...
Source: European Urology - Category: Urology & Nephrology Source Type: research